What do systematic reviews say?

Children: prednisolone vs dexamethasone

• Different oral corticosteroid regimens for acute asthma 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 255 participants
  GRADE not reported

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.63 [0.21, 1.91]
  2 studies · 512 participants
  Low

Budesonide vs mesalamine

Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.75 [0.17, 3.28]
  1 study · 254 participants
  Low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 3.94 [0.45, 34.74]
  1 study · 254 participants
  Low

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.88 [0.33, 2.4]
  2 studies · 513 participants
  Low

RISPERIDONE DEPOT vs OLANZAPINE

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.1 [0.8, 1.51]
  1 study · 547 participants
  Low

Methadone vs oral slow‐release morphine

• Maintenance agonist treatments for opiate‐dependent pregnant women 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  Low

RISPERIDONE DEPOT vs QUETIAPINE

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 0.84 [0.62, 1.13]
  1 study · 666 participants
  Low

Tofacitinib vs placebo

Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).

• Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 0.81 [0.42, 1.59]
  1 study · 592 participants
  Low

IV ferric carboxymaltose vs oral iron

It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 8.81 [0.52, 149.07]
  1 study · 200 participants
  Very low

IV iron isomaltoside vs oral iron

It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 4.02 [0.51, 31.73]
  1 study · 338 participants
  Very low

IV iron sucrose vs oral iron

It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 3.07 [0.13, 73.32]
  1 study · 91 participants
  Very low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 0.96 [0.66, 1.39]
  2 studies · 729 participants
  Very low

IPV‐OPV vs OPV

IPV‐OPV showed no clear difference in serious adverse events (classified by MedDRA) (Range of compared with OPV (low certainty).

• Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
  RR 0.88 [0.46, 1.7]
  4 studies · 1948 participants
  Low

Macrolide+tetracycline vs macrolides

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

• Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  OR 1 [0.52, 1.93]
  1 study · 198 participants
  Very low

Intervention not reported

• Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  GRADE not reported

Intervention not reported

• Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 114 participants
  GRADE not reported

Intervention not reported

The review found no eligible studies for this question.

• Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Boswellia serrata vs valdecoxib

• Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in adverse events Participants (n) reported serious adverse events (moderate certainty).

• Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
  RR 1.22 [0.94, 1.59]
  1 study · 398 participants
  Moderate